Semaglutide at a low dose: what to expect from the first weeks of treatment

Why does semaglutide start at such a small dose?

A question our prescribers hear regularly goes something like: "I've been on it a month and barely lost anything, is it working?" The honest answer is that at 0.25 mg, the medicine is not yet at a dose where the full appetite effect comes through. That is by design.

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone that slows how quickly the stomach empties and signals fullness to the brain. At higher concentrations those effects are pronounced. At 0.25 mg, the concentration is low enough to let the gut adapt, reducing the chance of severe nausea or vomiting when the therapeutic doses eventually land. The NHS patient information for semaglutide is clear that the starting dose is a tolerability measure, not the target.

After four weeks at 0.25 mg, the schedule moves to 0.5 mg, then 1.0 mg, a step where many people begin to notice a more meaningful shift in appetite, then 1.7 mg, and finally 2.4 mg, or, for the newer 7.2 mg pen, continues beyond that under prescriber direction. If you want a fuller picture of where each step sits in the sequence, the overview of the full Wegovy dose schedule covers the whole ladder. The prescriber decides when each increase happens; some people stay longer at one level if tolerability needs more time.

What actually happens to appetite and weight at a low semaglutide dose?

Some people notice a meaningful drop in hunger even at 0.25 mg. Others notice almost nothing until the dose climbs. Both are normal, and neither predicts how well the medicine will work at maintenance. The GLP-1 mechanism is dose-dependent, so the appetite suppression deepens as the schedule progresses.

The trial evidence bears this out. In the STEP 1 study (a 68-week randomised trial of 2.4 mg semaglutide versus placebo published in the New England Journal of Medicine) the average weight reduction across participants was around 15%. That figure reflects the full 68 weeks, most of which were spent at maintenance dose. The low-dose weeks are the foundation, not the structure. Meaningful weight loss builds during and after the titration phase, not during the 0.25 mg week alone.

If you are curious about specific millilitre volumes for each dose (useful if you have ever tried to compare pen fill information) the guide to semaglutide doses expressed in ml explains how the pen system works in practice.

What side effects are most common during the low-dose weeks?

Here is the thing people often get backwards: the low-dose phase is not always the easiest phase. For many people, nausea is actually most noticeable in the first few weeks, before the body settles. Constipation, loose stools, burping, indigestion and fatigue are also reported. They are generally mild to moderate and tend to ease within two weeks of each dose step.

A few practical notes. Eating smaller portions and avoiding very fatty or spicy meals during the start phase genuinely helps. Staying hydrated matters, if vomiting or diarrhoea is prolonged, there is a real risk of dehydration. Persistent, severe stomach pain that radiates toward the back needs prompt medical attention; this is the warning sign associated with pancreatitis, which the MHRA highlighted in a Drug Safety Update in January 2026. If you experience that, stop the medicine and seek urgent care. Suspected side effects can be reported to the MHRA via the Yellow Card scheme.

The decision about how to manage any side effect during titration sits with your prescriber. At nume, aftercare is available seven days a week precisely for moments like these, questions in the first fortnight are common, not exceptional.

When does a prescriber consider staying at a low semaglutide dose longer?

The four-week intervals in the standard schedule are a guide, not a fixed rule. If tolerability is poor (if nausea is still interfering with daily life at the end of week four) a prescriber may recommend holding at the current dose for another month before moving up. That is clinically appropriate and is not a sign that the medicine is failing.

There is a common misconception that staying at a low dose longer will reduce eventual weight loss. There is no good evidence for that. The titration exists to reach maintenance safely; the timeline for getting there is secondary to getting there comfortably enough to stay on treatment. What does matter for long-term outcomes is reaching and sustaining a maintenance dose, and that is far more likely when the early phase is managed well. For a deeper look at how individual doses along the Wegovy titration compare, the page on semaglutide dosing covers the clinical context in more detail.

If you are further along and curious about the step immediately above the starter, the 2 mg semaglutide dose page explains where that sits in the schedule. And for a broader look at what private treatment involves (including how cost is structured) the Wegovy cost page sets out what to expect without any hidden fees. When you are ready to talk to a prescriber, starting a free consultation is the first step.